Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection

Hepatology. 2013 Oct;58(4):1277-86. doi: 10.1002/hep.26489. Epub 2013 Aug 19.

Abstract

Given the clinical significance of hepatitis B e antigen (HBeAg) seroconversion in chronic hepatitis B virus (HBV) infection, it is critical to elucidate the mechanisms regulating this process. In the present study, we found that the frequency of circulating chemokine (C-X-C motif) receptor 5 (CXCR5)(+) CD4(+) T cells was higher in patients who had achieved HBeAg seroconversion in both cross-sectional (P < 0.001) and longitudinal (P = 0.009) studies. These cells were able to produce a significantly higher level of intracellular interleukin 21 (IL-21) after stimulation with HBV peptides in patients with telbivudine-induced HBeAg seroconversion (P = 0.007). Furthermore, sorted CXCR5(+) CD4(+) T cells from HBeAg seroconverters boosted a higher frequency of antibody against hepatitis B e antigen (anti-HBe)-secreting B cells in coculture assay (P = 0.011). Of note, the increase in frequency of anti-HBe-secreting B cells was abrogated by soluble recombinant IL-21 receptor-Fc chimera (P = 0.027), whereas exogenous recombinant IL-21 enhanced this effect (P = 0.043). Additionally, circulating CXCR5(+) CD4(+) T cells shared similar phenotypic markers, and were positively correlated in frequency with, splenic follicular T helper cells.

Conclusion: Circulating CXCR5(+) CD4(+) T cells, by producing IL-21, may have a significant role in facilitating HBeAg seroconversion in patients with chronic HBV infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Viral / blood*
  • Antiviral Agents / therapeutic use
  • Biomarkers / blood
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / metabolism*
  • CD4-Positive T-Lymphocytes / pathology*
  • Cells, Cultured
  • Cross-Sectional Studies
  • Female
  • Hepatitis B e Antigens / blood*
  • Hepatitis B virus / immunology
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / immunology*
  • Hepatitis B, Chronic / metabolism
  • Humans
  • In Vitro Techniques
  • Interleukins / metabolism*
  • Interleukins / pharmacology
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Phenotype
  • Receptors, CXCR5 / metabolism*
  • Recombinant Proteins / pharmacology
  • Telbivudine
  • Thymidine / analogs & derivatives
  • Thymidine / therapeutic use
  • Young Adult

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Biomarkers
  • CXCR5 protein, human
  • Hepatitis B e Antigens
  • Interleukins
  • Receptors, CXCR5
  • Recombinant Proteins
  • Telbivudine
  • interleukin-21
  • Thymidine